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Jean Beissel6 and Ala’a Alkerwi2Abstract
Background: Cardiovascular disease is the number one cause of death in the United States and in most European
countries. Cardiovascular health, as defined by the American Heart Association, is comprised of seven health metrics
(smoking, body mass index, physical activity, diet, total cholesterol, blood pressure, and fasting plasma glucose). No
studies have compared US data with data collected elsewhere, using this index of cardiovascular health
Methods: We performed comparative analyses of cardiovascular health status in participants from 2 study sites in 2
different countries: the Maine-Syracuse Study, conducted in Central New York, USA in 2001–2006 (n = 673), and the
Observation of Cardiovascular Risk Factors in Luxembourg, conducted in 2007–2009 (n = 1145).
Results: The Cardiovascular Health Score, the sum of the total number of metrics at ideal levels, was higher in the
Luxembourg site than in the Central New York site. Ideal cardiovascular health levels for body mass index, smoking,
physical activity, and diet were more prevalent in the Luxembourg site than the Central New York site. Ideal levels
for blood pressure were more prevalent in Central New York. Differences between the two sites remained with
control for age, gender and socioeconomic indicators.
Conclusions: Cardiovascular health, as indexed by seven health metrics, was higher in the European study site than
in the US study site. The largest differences were for the four lifestyle/behavior metrics, namely body mass index,
smoking, physical activity, and diet. Preventative and intervention strategies will continue to be important for both
countries in order to improve cardiovascular health.
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Cardiovascular disease (CVD) accounts for approximately
one of every three deaths in the United States, and is esti-
mated to cost $312 billion annually [1]. The American
Heart Association (AHA), in its recently released ‘Strategic
Impact Goal Through 2020 and Beyond’ defined levels of
four health behaviors (not smoking, engaging in sufficient
physical activity, consuming a healthy diet, and body mass
index (BMI) less than 25 kg/m2), and three health factors
(optimal total cholesterol, blood pressure (BP), and fasting* Correspondence: whige003@mymail.unisa.edu.au
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unless otherwise stated.blood glucose), to identify ideal cardiovascular health [2]. A
number of investigators have used this construct and re-
ported low prevalences of ideal cardiovascular health in US
samples [3-5]. Furthermore, negative correlations between
ideal cardiovascular health and all-cause and CVD mortal-
ity [4,6], and cardiovascular events [4,5,7,8] have been iden-
tified. Our literature search showed little evidence that
attention has been paid to this concept outside of the USA.
Moreover, comparisons between the prevalence of poor,
intermediate and ideal cardiovascular health levels at
study sites in the USA and other countries have not been
undertaken.
In order to make a cross-national comparison, we used
data collected from two prominent studies with similar data
on CVD risk factors, health behaviors, and demographicl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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in the United States, and the Observation of Cardiovascular
Risk Factors in Luxembourg (ORISCAV-LUX). The MSLS
was conducted in Syracuse, New York (NY), USA and
its catchment area (Central NY). ORISCAV-LUX was a
nation-wide, population-based study. Several considerations
make these specific comparisons important and meaning-
ful. First, existing multinational data collection efforts (e.g.,
Health and Retirement Study in the USA/Survey of Health,
Ageing and Retirement in Europe) do not measure key as-
pects of cardiovascular health (e.g., diet, total cholesterol,
BP) and we know of no nationally representative data set
that permit comparisons on these indices. Second, the
MSLS and ORISCAV-LUX collect measures in essentially
identical fashions, and both samples are representative
of their respective geographic areas. Data collected from
Luxembourg are of particular interest due to the multi-
national nature of its population, with a large number of in-
dividuals originating from neighboring European countries
living in Luxembourg. As in the US, CVD is the number
one cause of mortality in Luxembourg, with CVD related
illnesses accounting for 33.8% of all deaths in 2011 [9].
Our overall objective was to compare the pattern of
cardiovascular health between two geographically and
culturally distinct sites in the US and in Luxembourg.
Specifically, the first objective was to compare the sites
with respect to the total number of health metrics at
ideal levels, indexed by a global Cardiovascular Health
Score (CHS), derived from the AHA construct of cardio-
vascular health. The second objective was to examine
the prevalence of poor, intermediate, and ideal health for
each health behavior (smoking, physical activity, diet,
BMI), and health factor (total cholesterol, BP, and fasting
blood glucose) at each site. The third objective was to
assess whether any observed differences in the cardio-
vascular health components between the two study sites
remained after controlling for socioeconomic indicators.
As European countries have higher rates of walking,
cycling, and active transportation than in the United
States [10], and a number of studies have shown an
inverse association between active transportation and
overweight/obesity, BP, and triglyceride and fasting insu-
lin levels [10-15], we hypothesised that the CHS would
be higher in the Luxembourg site than in the Central
NY site. With regard to the individual health metrics, we
postulated that the prevalence of ideal levels for physical
activity and BMI would also be higher in Luxembourg
than Central NY.
Methods
Participants in MSLS (USA)
The MSLS is a community-based study of aging, cardio-
vascular risk factors and cognitive functioning in adults,
aged 23–98 years [16-19]. At initial recruitment, the soleexclusions were institutionalized people, diagnosed alco-
holism and psychiatric disorder. The data for the present
study were taken from subjects returning for the 6th
(2001–2006) study wave when dietary intake measures
were first obtained. At this time, 80.7% of participants
were residing in Onondaga County and 10.1% in 3 coun-
ties surrounding Onondaga County in the Central NY
area of upstate New York State. The remaining original
residents of Central NY (9.2%) had relocated to 1 of 15
different states at the time this study was conducted.
Demographics and health statistics published for Onondaga
County, NY, best describe this sample [20]. Beginning with
a sample of 1049 individuals, participants were excluded
from the present analysis for the following reasons: missing
dietary or cardiovascular health data (n = 34), acute stroke
(n = 28), probable dementia (n = 8), hemo-dialysis (n = 5),
inability to read English (n = 1), and alcohol abuse after
baseline (n = 1), leaving 972 participants.
Participants in ORISCAV-LUX (Luxembourg)
ORISCAV-LUX, a nationwide, cross-sectional study con-
ducted in 2007–2009, was designed to gather information
on the prevalence of cardiovascular risk factors among the
adult population of Luxembourg. Exclusions were institu-
tionalized people (n = 12), pregnancy (n = 21), serious men-
tal and/or physical handicap (n = 5), prisoners (n = 1),
people outside the determined age range (n = 2) and those
deceased before recruitment (n = 5) [21]. A representative
random sample of 1432 individuals, stratified by sex, age
(18–69 years) and district of residence completed the re-
cruitment procedure [21,22]. After eliminating those with
missing data on components of cardiovascular health, data
were available for 1352 of the ORISCAV-LUX sample.
Final comparative sample
In both studies only participants aged 30–69 were in-
cluded in order to compare two age-homogeneous sam-
ples. The final sample comprised 1818 individuals (673
from MSLS and 1145 from ORISCAV-LUX). Further
details related to the methods of sampling for both stud-
ies appear elsewhere [18,19,21,22]. All participants gave
informed written consent to take part. The MSLS was
approved by the University of Maine Institutional Review
Board and ORISCAV-LUX by the National Research Ethics




Participants at both study sites underwent physical and
anthropometric measurements, blood tests, and com-
pleted self-administered questionnaires to gain informa-
tion on demographic and socioeconomic characteristics.
Standardized protocols for data collection were used.
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as described previously for both studies [16,18,19,21-23].
Standard assay methods were employed [18,23] to
obtain fasting plasma glucose (mg/dl) and total choles-
terol (mg/dl).
In the MSLS, physical activity was measured with the
Nurses’ Health Study (NHS) Activity Questionnaire [24].
Dietary intake was assessed using the food frequency
questionnaire (FFQ) component of the Nutrition and
Health Questionnaire [25]. Smoking status was based on
self-report from the same questionnaire [25]. At the con-
clusion of each wave, MSLS subjects were informed of any
new risk factors detected at that examination and advised
to consult their physician for treatment.
In ORISCAV-LUX, physical activity was measured
using the short format International Physical Activity
Questionnaire (IPAQ) [26]. Detailed data regarding
smoking were obtained from the health questionnaire.
Dietary intake was assessed using a semi-quantified
FFQ assessing the frequency of consumption of 134
items [27]. All questionnaires used in ORISCAV-LUX
were available in French, English, German, and Portuguese.
ORISCAV-LUX subjects were advised to see their physi-
cians for treatment if any cardiovascular anomaly was
detected during the study assessment.
Diet metric
For the diet metric, two food scores were calculated for
each study, a Recommended Food Score (RFS) [28], and
a non-Recommended Food Score (non-RFS) [29]. These
scores were used according to the availability of dietary
data in order to capture a detailed measure of dietary
intakes. The RFS comprised 18 food items, based on the
recommendations of the 2010 Dietary Guidelines for
Americans [30]. One point was awarded for consump-
tion of any of the recommended foods at least once per
week (fruit, vegetables, legumes, wholegrain cereal prod-
ucts, low fat dairy products, fish, nuts), otherwise 0 points
were given [28], to give a total score out of 18. Included
foods were similar to those used previously [28,31,32].
The non-RFS [29] included 13 items that are recom-
mended to reduce [30], including processed meats, refined
grains, solid fats, added sugars, and alcohol. Consumption
of non-recommended foods at least two to four times per
week was assigned a score of 1; otherwise 0 points were
assigned [31,33]. A total non-RFS out of 13 was calculated,
with a higher value indicating a higher consumption of
non-recommended food items.
Cardiovascular health score
Poor, intermediate, and ideal health levels for smoking,
BMI, physical activity, total cholesterol, BP, and fasting
plasma glucose were calculated using the AHA defini-
tions [2] (see Online Resource 1). For the RFS, scores of0–7, 8–11, and 12–18 were defined as poor, intermedi-
ate, and ideal, respectively. Scores of 5–13, 3–4, and 0–2
for the non-RFS were defined as poor, intermediate, and
ideal.
The CHS comprised the sum of components at ideal
levels, ranging from 0 (no cardiovascular health compo-
nents at ideal levels) to 8 (all cardiovascular health com-
ponents at ideal levels). This global score was then
categorized into low (0–2 components at ideal levels),
medium (3–5) or high (6–8).
Data analysis
According to the type of variable (continuous or cat-
egorical), independent samples t-tests and Chi-square
tests were used to compare demographic variables, mean
scores of the cardiovascular health metrics and other
health variables in the two samples (n = 673 for MSLS,
n = 1145 for ORISCAV-LUX).
The proportion of each sample in the poor, intermediate
and ideal categories for each cardiovascular health metric
were calculated. As prevalence estimates are strongly gen-
der and age-dependent (e.g., risks increase for chronic
diseases with age), prevalence comparisons between popu-
lations may be misleading if the underlying age and/or
gender composition differs in the populations being
compared [34]. To overcome this, direct gender and
age standardization according to the Segi world stand-
ard population was used to compute gender and age
standardized prevalence in each health category [35].
Prevalence of each health category (e.g., poor health) for
each health metric in the two study sites were compared by
computing the comparative morbidity ratio and testing it
for statistical significance [36]. This was also performed for
the global CHS (comparing low, medium and high categor-
ies between the two sites).
General linear models were used to examine associa-
tions between study site and each cardiovascular health
component (as continuous variables). Statistical adjust-
ment was made for age, gender, education and income.
Interactions of study site with gender and age were not
significant. SPSS version 21 and SAS (version 6.1) were
used for all analyses. P values of <0.05 were considered
statistically significant.
Sensitivity analyses were performed excluding the mi-
nority populations in each sample (n = 52 in ORISCAV-
LUX and n = 65 in MSLS) and excluding the persons
residing in states other than NY at the time of wave




Table 1 shows the demographic, cardiovascular health
components, and other health variables for MSLS and
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higher proportion of participants who were obese, had
diagnosed hypertension, diabetes, or CVD (all p < 0.001),
compared with the Luxembourg sample. The proportion of
those treated for diagnosed hypertension was significantly
higher at the Central NY site (84.3%) than in Luxembourg
(37.7%) (p < 0.001).
Cardiovascular health
Health behaviors
As shown in Table 1, BMI was significantly higher in
the Central NY sample than in the Luxembourg sample
(p < 0.001). The dietary measures indicated a lower in-
take of recommended foods and a higher intake of
non-recommended foods at the Central NY site com-
pared with intakes at the Luxembourg site (both p < 0.001).
Cigarettes smoked per day and time spent engaging in
weekly physical activity were both higher at the Luxembourg
site than at the Central NY site (both p < 0.01).
The observed differences in BMI, physical activity and
diet (RFS and non-RFS) remained statistically significant
with the additional adjustment for age, gender, education,
and income (all p < 0.001) (Table 2). Weekly physical activ-
ity time was over two times higher in the Luxembourg
sample than in the Central NY sample. This difference
remained significant in secondary analyses with statistical
adjustment for BMI, waist circumference and waist/hip ra-
tio (data not shown).
Health factors
Fasting plasma glucose was significantly higher in the
Central NY sample than in the Luxembourg sample (p <
0.001), while mean systolic and diastolic BP were both sig-
nificantly higher in Luxembourg (both p < 0.001) (Table 1).
BP measures, as well as total cholesterol were significantly
higher in Luxembourg than in the Central NY site when
adjusted for age, gender, education, and income (Table 2).
The BP difference was unchanged with statistical adjust-
ment for BMI, waist circumference and waist/hip ratio
(data not shown).
Total cardiovascular health score
The mean total CHS (number of metrics at ideal levels)
was significantly higher at the Luxembourg site (4.2) than
at the Central NY site (3.8) (fully adjusted model, Table 2,
p < 0.001). The proportion of the sample with overall ‘ideal
health’ (8/8 components at ideal levels) was 1.0% at the
Luxembourg site, compared with 0.4% at the Central NY
site (not statistically significant).
Poor, intermediate and ideal cardiovascular health
comparison
The percentages of participants in ORISCAV-LUX and
MSLS with poor, intermediate and ideal health for eachhealth behavior and factor, and the global CHS (age and
gender standardized) are shown in Table 3. The percent-
age of those with ideal health was significantly higher in
the Luxembourg site than in the Central NY site for
BMI, smoking, physical activity and diet (both scores) (all
p < 0.01). The percentage of those with ideal BP levels was
higher in the Central NY site than in the Luxembourg site
(p < 0.001).
Poor health levels for BMI and diet (RFS and non-
RFS) were statistically significantly higher at the Central
NY site than at the Luxembourg site (all p < 0.05). Preva-
lence of poor levels for BP and total cholesterol were higher
in Luxembourg than in Central NY (both p < 0.001).
Figure 1 shows the proportion of participants in each
site (aged 30–69 years) with a low (0–2 health compo-
nents at ideal levels), medium (3–5 health components
at ideal levels), and high (6–8 health components at
ideal levels) CHS. A greater percentage of participants in
the Luxembourg site had a higher number of total health
components in the high category (CHS 6–8), than in the
Central NY site (p < 0.05).
Discussion
The present study is, to our knowledge, the first to make
cross-national comparisons using the AHA-defined
components of cardiovascular health. Although we are
unable to generalize beyond the two geographic study
sites in Central NY, USA and Luxembourg, the study
provides insight into how cardiovascular health differs
between two sites in the US and Europe. Luxembourg, a
centrally located European country with a large proportion
of the population coming from Portugal and neighboring
countries including Belgium, Germany and France, serves
as a good representation of western Europe. Syracuse and
its surrounding counties are ethnically diverse, and consti-
tute the economic and educational hub of Central NY state.
The overall CHS, generated from the individual health
metrics, was higher at the Luxembourg site than at the
Central NY site. Ideal levels for BMI, smoking, physical
activity, and diet were more prevalent in Luxembourg
than in Central NY. However, ideal levels for BP were
more prevalent in Central NY. Differences between the
two sites with respect to BMI, physical activity, diet and
BP cannot be attributed to age, gender, income and edu-
cation as findings remained after adjustment for these
potential confounders.
Importantly, the prevalence of overall ideal cardiovas-
cular health (ideal levels for all components) was low at
both the Central NY site (0.4%) and the Luxembourg site
(1.0%). This is consistent with smaller state-based stud-
ies and national data in the USA, with prevalences ran-
ging from 0–0.1% [1,3,5] to 1.2% [4]. Of concern are the
national (US) data indicating that the prevalence of ideal
cardiovascular health decreased from 2.0% in 1988–1994
Table 1 Demographic, cardiovascular and health variables for MSLS (n = 673) and ORISCAV-LUX (n = 1145) participants
Variable Central New York MSLS Luxembourg ORISCAV-LUX p-value
M or % SD M or % SD









Q1 (< 30 000) 23.8 17.8
Q2 (30 000 to 60 000) 37.6 51.0
Q3 (60 000–120 000) 35.3 25.8





Smoking, no cigarettes per day (all) 1.7 5.7 2.7 7.2 0.002
Smoking, no cigarettes per day (smokers) 13.0 10.2 14.6 10.3 0.23
BMI, kg/m2 29.9 6.3 27.1 4.9 <0.001
Physical activity, mins/wk2 273 345 778 936 <0.001
Total cholesterol, mg/dl 203.6 39.8 206.3 39.7 0.17
Systolic BP, mm Hg 126.8 20.7 131.6 18.2 <0.001
Diastolic BP, mm Hg 70.8 10.2 83.8 10.9 <0.001
Fasting blood glucose, mg/dl 98.4 28.9 94.5 18.6 <0.001
RFS, 0-183 9.2 2.8 10.8 2.8 <0.001
non-RFS, 0-134 3.3 1.6 3.0 1.6 <0.001
Total CHS, 0-8 3.8 1.6 4.2 1.6 <0.001
Proportion of sample with CHS 0/8 0.7 0.3 0.25
Proportion of sample with CHS 8/8 0.4 1.0 0.17
Other health measures
Height, cm 168.7 9.8 169.4 9.8 0.13
Weight, kg 85.3 20.2 78.1 16.5 <0.001
Waist circumference, cm 95.6 15.6 91.4 13.5 <0.001
Hip circumference, cm 109.2 12.5 101.6 9.5 <0.001
Waist:hip 0.87 0.09 0.90 0.09 <0.001
CRP, mg/dL 0.41 0.46 0.27 0.48 <0.001
Alcohol intake, standard drinks/d 0.5 1.0 1.3 1.3 <0.001
Obese, BMI≥ 30 kg/m2 42.1 25.5 <0.001
Diabetes5 10.7 5.8 <0.001
Treated participants with diabetes 79.2 65.2 0.07
Treated diabetes: fasting blood glucose, mg/dl 156.3 65.3 152.7 45.4 0.76
Untreated diabetes: fasting blood glucose, mg/dl 143.7 21.3 138.4 15.1 0.37
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Table 1 Demographic, cardiovascular and health variables for MSLS (n = 673) and ORISCAV-LUX (n = 1145) participants
(Continued)
Hypertension6 54.8 43.3 <0.001
Treated participants with hypertension 84.3 37.7 <0.001
Treated hypertension: systolic BP, mm Hg 134.4 20.1 145.4 18.7 <0.001
Treated hypertension: diastolic BP, mm Hg 73.4 9.4 89.2 11.3 <0.001
Untreated hypertension: systolic BP, mm Hg 152.3 13.1 146.0 14.9 0.003
Untreated hypertension: diastolic BP, mm Hg 81.2 11.1 93.5 8.5 <0.001
CVD7 11.3 4.0 <0.001
1US $ or euros per year.
2Includes moderate and vigorous physical activity.
3Higher scores indicate higher intake of recommended foods.
4Higher scores indicate higher intake of non-recommended foods.
5Fasting plasma glucose ≥ 126 mg/dL or taking anti-diabetic medication.
6Had systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg or taking anti-hypertensive medication.
7Includes myocardial infarction, coronary artery disease, heart failure, angina pectoris, transient ischemic attack.
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in physical inactivity and obesity, and decreases in fruit and
vegetable consumption have been observed [37]. The big-
gest prevalence differences between the two present studies
were observed for the RFS. Poor health for this score in the
Central NY sample (34.5% of participants) was nearly three
times higher than in Luxembourg (11.8% of participants).
The role of physical activity in weight control is well
established. While the age-adjusted proportion of partic-
ipants not engaging in any physical activity was similar
in both study sites (10-12%), the mean time spent en-
gaging in physical activity per week was over two times
higher in the Luxembourg site than Central NY, equat-
ing to a difference of approximately 6.5 hours per week.
Adjusting for BMI, waist circumference and waist/hipTable 2 Multivariate-adjusted means1 and SE for total Cardio
MSLS (n = 673) and ORISCAV-LUX (n = 1145)
Cardiovascular Health variable Central New York MSLS
M SE
Total Cardiovascular Health Score, 0-8 3.8 0.08
Cardiovascular Health metrics
Smoking, no cigarettes per day 2.3 0.34
BMI, kg/m2 29.9 0.26
Physical activity, mins/wk2 358 46
Total cholesterol, mg/dl 201.3 2.04
Systolic BP, mm Hg 122.7 0.85
Diastolic BP, mm Hg 70.1 0.52
Fasting blood glucose, mg/dl 96.1 1.03
RFS, 0-183 8.9 0.14
non-RFS, 0-134 3.5 0.08
1Adjusted mean values for age, gender, education and income.
2Includes moderate and intense physical activity.
3Higher scores indicate higher intake of recommended foods.
4Higher scores indicate higher intake of non-recommended foods.ratio in secondary analyses did not change the results
(data not shown). This is consistent with data showing
that Europeans walk and cycle over two and four times,
respectively, the number of kilometres per person per
year, than residents of the United States [10]. Further-
more, active transportation via walking or cycling is also
more common in Europe than in North America and
the lowest estimates of adult obesity are found in coun-
tries that rely more upon active transportation and less
upon automobiles [10,11]. As per intuition, higher rates
of walking and cycling as a means of transport have also
been associated with a higher percentage of adults meet-
ing the recommended levels of physical activity, as well
as lower estimates of diabetes [11]. The infrastructure
in Luxembourg supports walking and cycling for dailyvascular Health Score and cardiovascular health metrics,
Luxembourg ORISCAV-LUX Mean difference p-value
M SE
4.2 0.05 −0.38 <0.001
2.3 0.21 −0.04 0.93
27.0 0.17 2.89 <0.001
754 26 −396 <0.001
207.4 1.30 −6.08 0.017
132.7 0.54 −9.94 <0.001
83.9 0.33 −13.85 <0.001
94.7 0.65 1.37 0.29
10.9 0.09 −2.0 <0.001
3.0 0.05 0.55 <0.001
Table 3 Age- and gender-standardized proportions of participants in the MSLS (n = 673) and ORISCAV-LUX (n = 1145),
with poor, intermediate and ideal health for each health component, and for the global Cardiovascular Health Score






Poor ≥30 kg/m2 43.0 25.4 <0.001
Intermediate 25-29.9 kg/m2 34.5 35.0 0.88
Ideal <25 kg/m2 22.5 39.6 <0.001
Smoking
Poor Current smoker 16.6 18.8 0.43
Intermediate Former smoker, quit < 12 months 54.5 28.6 <0.001
Ideal Never or quit > 12 months 29.0 52.6 <0.001
Physical activity
Poor No physical activity 10.6 11.9 0.58
Intermediate 1-149 min/wk moderate intensity activity2 30.0 19.8 0.001
Ideal ≥ 150 min/wk moderate intensity activity3 59.5 68.3 0.013
Fasting plasma glucose
Poor ≥126 mg/dL 5.6 4.8 0.48
Intermediate 100-125 mg/dL or treated to goal 15.4 21.4 0.021
Ideal <100 mg/dL 79.0 73.8 0.056
Total cholesterol
Poor ≥240 mg/dL 11.6 19.6 <0.001
Intermediate 200-239 mg/dL or treated to goal 37.4 33.5 0.20
Ideal <200 mg/dL 51.0 46.9 0.21
Blood pressure
Poor Systolic BP ≥140 or diastolic BP ≥90 mm Hg 18.4 38.5 <0.001
Intermediate Systolic BP 120–139 or diastolic BP 80–80 mm Hg
or treated to goal
33.0 38.6 0.10
Ideal <120/80 mm Hg 48.6 23.0 <0.001
RFS4
Poor 0-7 34.5 11.8 <0.001
Intermediate 8-11 48.8 45.5 0.34
Ideal 12-18 16.7 42.8 <0.001
non-RFS5
Poor 5-13 24.9 18.4 0.047
Intermediate 3-4 45.5 42.7 0.41
Ideal 0-2 29.6 38.9 0.005
Global CHS
Low 0-2 components in ideal range 19.6 15.2 0.12
Medium 3-5 components in ideal range 65.2 64.1 0.76
High 6-8 components in ideal range 15.2 20.6 0.049
1Definitions according to the American Heart Association except for diet score, for adults >20 years of age.
2Or 1–74 min/wk vigorous intensity activity.
3Or ≥75 min/wk vigorous intensity activity.
4RFS scored out of 18, with higher scores indicating a higher consumption of recommended foods to increase.
5non-RFS scored out of 13, with higher scores indicating a higher consumption of foods recommended to reduce.
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the difference observed in the present study. During the
period of data collection for MSLS, the automobile wasthe predominant mode of transportation in Syracuse and
Central New York with few cycling paths on city and
town streets.
Figure 1 Proportion of Maine-Syracuse Longitudinal Study (MSLS) and Observation of Cardiovascular Risk Factors in Luxembourg
(ORISCAV-LUX) participants (aged 30–69 years) with low (0–2 health components at ideal levels), medium (3–5 health components at
ideal levels), and high (6–8 health components at ideal levels) Cardiovascular Health Score. p-values represent significant differences in
proportions between the 2 sites.
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adjusted BP was 133/84 mmHg in the Luxembourg
sample compared with 123/70 mmHg in the Central
NY sample. Epidemiological research utilizing national
survey data from six European countries, the US and
Canada, also found higher BP levels in Europe, and re-
ported very similar levels to those in the present study:
136/83 mmHg in Europe and 127/77 mmHg in North
America [38]. Of note, less than 40% of those with diag-
nosed hypertension in the Luxembourg sample were be-
ing treated for high BP, compared with nearly 85% in the
MSLS. Although hypertension has the same classifica-
tion in the US and Europe (systolic BP ≥140 mmHg
and/or diastolic BP ≥90 mmHg) [39,40], the initial ap-
proaches to BP control vary and we can only speculate
that this may contribute to the BP differences observed
[39,40]. Lifestyle modification and immediate initiation
of antihypertensive drug therapy is recommended in the
US [40], whereas in Europe, the immediate initiation of
drugs needs the presence of other symptomatic CVD
risk factors [39].
In addition, poor awareness of relatively ‘silent’,
asymptomatic cardiovascular risk factors including
hypertension and dyslipidemia has been demonstrated
in this Luxembourg population, with 60% unaware of
their diagnosed hypertension (diagnosis made from theORISCAV-LUX survey) [41]. This level of unawareness
is two-fold that of the US; national estimates from the
National Health and Nutrition Examination Survey 1999–
2000 data indicate an unawareness level of 30% [40].
There are several study limitations. ORISCAV-LUX was
a community, national population-based study, whereas
MSLS was a community-based sample restricted to Central
NY. The MSLS sample is not nationally representative, but
both Luxembourg and the Syracuse metropolitan statistical
area (MSA) have similar population sizes of slightly more
than half a million inhabitants. In 2008, Central NY state
had an almost identical age-adjusted CVD mortality esti-
mate as the US (244.0 versus 244.8 per 100,000 deaths
[42,43]. In Onondanga County, NY, CVD mortality esti-
mates have been decreasing, following a national trend
[42,43]. While African Americans have been found to have
significantly fewer ideal cardiovascular health components
than whites [3,5], a sensitivity analysis excluding African
Americans (9.7% in MSLS) did not affect the pattern of re-
sults. Smoking, diet and physical activity data were based
on participant self-report and the same instruments were
not used in both studies.
There are several study strengths. This is the first
study to compare three levels of cardiovascular health in
two studies from two different countries. We are not
aware of published data using ideal cardiovascular health
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estimates across these two samples with different age
compositions, the effects of variation in age structure
were removed by using a ‘world’ standard population
to standardize age [34]. The prevalence differences ob-
served in these analyses were confirmed when compari-
sons between the two sites were made using the health
metrics as continuous variables, with the added control
of education and income.
The purpose of our study was solely to describe the
epidemiological patterns of cardiovascular health in
these two study sites. The contrasts found are of sub-
stantial magnitude, however the findings neither pro-
vide causal explanations nor effectiveness data on the
health care system in either region.
Conclusions
The main finding of note in the present study is in the
recognition that the majority of participants at both
study sites had overall cardiovascular health scores that
fell within the intermediate range, but the overall CHS
was higher in Luxembourg. The differences found for
the BP, diet, and physical activity metrics are particularly
notable. As both Luxembourg and the New York State
Department of Health have implemented public health
policies to promote and maintain population cardiovas-
cular health [44,45], it is difficult to attribute findings to
specific health care policies, particularly as health care
delivery is different in each region.
However the current findings suggest that different
strategies for intervention will be important for different
countries and underscore the need for cross-national
comparisons. The continued improvement of education
programs and focus on prevention measures may be helpful
in both countries. Infrastructure to support active means of
transportation may be an important consideration. Regard-
less of the approaches taken to achieve CVD reduction,
even small health behavior changes at a population level
would produce relatively large increases in the proportion
of individuals in both ideal and intermediate categories [1].
In a similar vain, small reductions in weight gain over de-
cades may accumulate into meaningful reductions in risk
for obesity-related disorders [46]. The impact on US mor-
tality from poor dietary habits is significant [47], yet simple
changes, such as dietary reduction of 3 g of salt per day, is
projected to yield substantial reductions in mortality and
health care costs [48]. For example, the total costs of diag-
nosed diabetes in the US was estimated at $245 billion in
2012 [49], and costs approximately €148 million per year in
Luxembourg [50]. Early intervention strategies to increas-
ing physical activity, make healthier food choices, cease
smoking, and lower blood sugar levels all seem important
based on our findings, and may help to produce significant
savings in health care costs in the long term. It may beparticularly important for future studies to focus on chil-
dren and young adults [51] in relation to interventions
designed to raise the AHA cardiovascular health metrics to
higher levels.
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